NCT02946879View on ClinicalTrials.gov

Long-Term Follow-Up Gene Therapy Study for Leber Congenital Amaurosis OPTIRPE65 (Retinal Dystrophy Associated With Defects in RPE65)

CompletedOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

July 31, 2023

Study Completion Date

July 31, 2023

Conditions

Leber Congenital Amaurosis (LCA)Eye DiseasesEye Diseases, HereditaryRetinal Diseases

Interventions

BIOLOGICAL

AAV OPTIRPE65

comparison of different doses of AAV RPE65

Trial Locations (2)

48105

Kellogg Eye Center, University of Michigan Health, Ann Arbor

Unknown

Moorfields Eye Hospital NHS Foundation Trust, London

All Listed Sponsors

lead

MeiraGTx UK II Ltd

INDUSTRY

NCT02946879 - Long-Term Follow-Up Gene Therapy Study for Leber Congenital Amaurosis OPTIRPE65 (Retinal Dystrophy Associated With Defects in RPE65) | Biotech Hunter | Biotech Hunter